Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.

Our mission is to improve and save the lives of people around the world by developing and delivering innovative medicines, treatments and vaccines that enable people to live longer, healthier lives.

Our vision is to be the most trusted and preferred pharmaceutical company, providing high-quality medicines and services to people with the highest standards of safety, efficacy and affordability.

Acurx has been the recipient of numerous awards, including the Barry Goldwater Award for Medical Excellence, the International Quality Award, and the President’s Choice Award for Quality Innovation and Excellence. We have also been recognized for our commitment to patient safety and our corporate social responsibility initiatives.